Personalis

Enzo Biochem and its subsidiary Enzo Life Sciences announced this week that the Patent Trial and Appeal Board has denied a petition filed by Hologic for inter partes review, a procedure for challenging the validity of patent claims, against US Patent 6,221,581.

The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.